Post-transplantation cyclophosphamide as graft versus host disease prophylaxis in patients with acute leukemia received fully matched allogeneic HSCT or haplo-identical HSCT

Post-transplant Cyclophosphamide (PT-Cy) has proved efficacy as GVHD prophylaxis regimen after HSCT. However, experiences are limited with controversial results. We herein, assess the of PT-Cy compared to Methotrexate regimen. Eighty patients acute leukemia received a fully matched allogeneic HSCT or Haplo-identical were analyzed. Group I (Historical group) included 40 Methotrexate, Cyclosporine and MMF. They transplanted transplantation. II PT-Cy, subdivided 2 subgroups. Subgroup IIA 22 allo- subgroup IIB 18 Haplo- showed significantly lower incidence cGVHD when group an 22.7% 67% respectively (P = 0.002). was associated reduced risk extensive MTX =0.003). No significant differences found in aGVHD, relapse rates, non-relapse related mortalities, OS DFS data among different groups (P>0.05). In conclusion, addition IS drugs statistically difference reducing cGvHD both Haplo SCT less hepatic renal toxicity.